Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC): a Phase I Trial to Identify a Dose of Dacomitinib in Combination With Pemetrexed That is Safe and Tolerated as Determined by the Incidence of Dose Limiting Toxicities (DLTs)
調査の概要
詳細な説明
This open label phase Ib trial aims to determine the safety, tolerability, the pharmacokinetic profile, and to identify a dose of dacomitinib in combination with pemetrexed.
Three sites in Austria will participate in this study. Six to nine patients will initially be enrolled to receive the target dose of 45 mg qd dacomitinib (starting from day 2 of first cycle) in combination with pemetrexed (500 mg/m² 10 min infusion, once every 3 weeks). One cycle is defined as 21 days.
The first 3 subjects will be enrolled at a rate of ≤ 1 subject per week. If the target dose regimen is safe based on the incidence of DLT another 3 subjects will be enrolled.
If the dose of 45 mg qd is not safe alternate lower doses will be explored (dose level -1, dose level -2) to identify the maximal tolerated dose (MTD) of dacomitinib in combination of pemetrexed. Six to nine patients per dose level will be enrolled.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Graz、オーストリア
- Medizinische Universität Graz Klinische Abteilung für Onkologie
-
Innsbruck、オーストリア
- Universitätsklinik für Innere Medizin I
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Written informed consent
- Histologically or cytologically confirmed stage IV non-squamous NSCLC
- Patients who are candidates to receive pemetrexed monotherapy
- If pemetrexed has been administered as first line therapy there must be a treatment free interval of at least one cycle (21 days)
- Measurable disease by RECIST criteria version 1.1.
- ≥18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
- Adequate left ventricular ejection fraction (LVEF) ≥ 50% by either echocardiogram or multigated acquisition scan (MUGA)
Adequate organ function, including:
- Adequate bone marrow reserve: absolute neutrophil count (ANC) should be ≥ 1500 cells/mm3, platelets should be ≥ 100.000 cells/mm3
- Creatinine clearance ≥ 45 mL/min
- Total bilirubin ≤ 1.5 x upper normal limit (ULN)
- Aspartate Aminotransferase (AST) (SGOT) ≤ 3 x ULN (≤ 5.0 x ULN if hepatic metastases)
- Alanine Aminotransferase (ALT) (SGPT) ≤ 3 x ULN (≤ 5.0 x ULN if hepatic metastases)
- Female patients or their partners must be postmenopausal (defined as 12 months of amenorrhea following last menses), surgically sterile or must agree to use effective contraception while receiving trial treatment and for at least 3 months thereafter (the definition of effective contraception will be based on the judgment of the investigator). Male patients or their partners must be surgically sterile or must agree to use a barrier method of contraception while receiving trial treatment and for at least 3 months thereafter. (In all cases the definition of effective contraception will be based on the judgment of the investigator).
- Able to comply with required protocol procedures and able to receive oral medications
Exclusion criteria:
- Any evidence of mixed histology that includes elements of small cell or carcinoid lung cancer
- Predominantly squamous cell histology
- Patients with symptomatic brain metastases
- Chemotherapy, radiotherapy, biological or investigational agents within two weeks of baseline disease assessments
Patients with uncontrolled or significant cardiovascular disease, including:
- Myocardial infarction within 12 months
- Uncontrolled angina within 6 months
- Congestive heart failure within 6 months
- Diagnosed or suspected congenital long QT syndrome
- Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
- Prolonged QTc interval on pre-entry electrocardiogram. QTc must be less than CTC Grade 2 (≤480 msec) using appropriate correction formula with manual read by investigator if required. The echocardiogram (ECG) may be repeated for evaluation of eligibility after management of correctable causes for observed QTc prolongation
- Any history of second or third degree heart block (may be eligible if currently have a pacemaker)
- Heart rate <50/minute on baseline electrocardiogram
- Uncontrolled hypertension
- Prior malignancy: Patients will not be eligible if they have evidence of other malignancy (other than non-melanoma skin cancer or in situ cervical cancer, or localized and presumed cured prostate cancer with prostate specific antigen (PSA) < ULN) within the last 3 years.
- Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior to study treatment start. Known hypersensitivity to pemetrexed and/or dacomitinib
- Patients with exposure to other investigational drug therapy
- Previous therapy with an oral tyrosine kinase inhibitor (TKI)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Dacomitinib, Pemetrexed
Pemetrexed 500mg/m2 (i.v) q21d Dacomitinib 45mg/ orally (continuous)
|
Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Dose Limiting Toxicities (DLTs)
時間枠:From start of treatment to end of treatment or death, whichever occurs first. The study was suspended after 36 months.
|
The primary objective of this study is to determine the maximal tolerated dose (MTD) of the combination pemetrexed + dacomitinib by the incidence of dose limiting toxicities (DLTs).
|
From start of treatment to end of treatment or death, whichever occurs first. The study was suspended after 36 months.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Overall Response Rate
時間枠:Until progression of disease (PD) or 24 month after end of treatment for participants with no PD. The study was suspended after 36 months
|
Overall Response Rate (ORR) is defined as the proportion of patients with complete Response (CR) or partial Response (PR).
|
Until progression of disease (PD) or 24 month after end of treatment for participants with no PD. The study was suspended after 36 months
|
Overall Survival
時間枠:until date of death. The study was suspended after 36 months.
|
Overall survival (OS) defined as time from start of Dacomitinib to date of death from any cause.
Patients without recorded death were censored at the date the patient was last known to be alive.
Patients were followed up for survival for 24 month after end of Treatment.
|
until date of death. The study was suspended after 36 months.
|
Progression-free Survival
時間枠:Up to progression or death due to any cause. The study was suspended after 36 months
|
Progression-free survival (PFS) defined as time from start of Dacomitinib to date of progression or date of death from any cause, whichever occurred first.
Patients without recorded progression or death were censored at the last date they were known to have not progressed.
Patients were followed up for progression-free survival for 24 month after end of Treatment.
|
Up to progression or death due to any cause. The study was suspended after 36 months
|
協力者と研究者
捜査官
- 主任研究者:Christoph C Zielinski, Univ. Prof.、Univ Clinic for Internal Medicine I, Dep of Oncology, Medical University of Vienna
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
非小細胞肺がんの臨床試験
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ
Dacomitinib, Pemetrexedの臨床試験
-
Instituto Nacional de Cancer, BrazilEli Lilly and Company完了